A carregar...

Déjà vu: EGF receptors drive resistance to BRAF inhibitors

The promise of personalized medicine is upon us, and in some cancers targeted therapies are rapidly becoming the mainstay of treatment for selected patients based on their molecular profile. The protein kinase BRAF is a driver oncogene in both thyroid cancer and melanoma, but whereas drugs that targ...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Girotti, Maria Romina, Marais, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3736320/
https://ncbi.nlm.nih.gov/pubmed/23658295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-13-0131
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!